Status of adjuvant endocrine therapy for breast cancer
Adjuvant endocrine therapy reduces the risk of recurrence and death from breast cancer in women with hormone receptor-positive early breast cancer. Tamoxifen has been the standard therapy for decades, and this is still the case for pre-menopausal women. Ovarian suppression is of similar efficacy but...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053079/ |